NCT07074756Recruiting
A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial
MC240703 Neuro-Oncology Anywhere: Glioma Home-Based Sequential Therapy (GHoST) Protocol
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
This clinical trial tests how well a digital treatment platform using a mobile application works for the delivery of home-based sequential therapy in patients with glioma. Access to specialized neuro-oncology care in the United States for patients with glioma is critically deficient. Care at centers with neuro-oncology specialists is associated with improved survival outcomes, yet many patients have limited access due to distance, disease-related disability, or lack of financial resources. The application provides patients continuous access to their care team in the home setting. A digital treatment platform may increase clinical trial participation and accelerate development of novel therapeutics while addressing a great health disparity in patients with glioma.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 202 (estimated)
- First submitted
- 9 Jul 2025
- Start date
- 12 Sept 2025
- Primary completion date
- 31 Aug 2028
- Lead sponsor
- Mayo Clinic
- Diseases
- Glioblastoma
- NCT number
- NCT07074756
What you commit to
- Study type: Interventional
- Planned participants: 202
- From 12 Sept 2025 to the primary completion date, 31 Aug 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
- SUBSTUDY 1: Uncontrolled and/or intercurrent illness or other condition which limits safety of or compliance with study proceedings
Other
- Pregnant or nursing, imprisoned, or lacking capacity for understanding
- SUBSTUDY 1: Pregnant or nursing, imprisoned, or lacking capacity for understanding
Who the study is looking for
- Age ≥ 18 years
- Diagnosis of glioma and intention to treat with either new or ongoing systemic therapy for at least 6 months.
- NOTE: Patient may be enrolled following completion of surgery and/or radiation therapy for newly diagnosed or recurrent tumor.
- NOTE: Any number of prior recurrences is permitted
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2, AND Karnofsky performance status (KPS) of ≥ 60
- Expected survival ≥ 6 months in the opinion of treatment team
- Willing and able to adhere with the protocol for the duration of the study including undergoing treatment, and attending scheduled visits, and examinations
- Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only
- Exception: Not required if patient is already on treatment. May be obtained prior to next treatment as needed per clinical care
- Provide written informed consent
- Ability to complete assessments and questionnaires by themselves or with assistance
- SUBSTUDY 1: Enrolled in GHoST Master Protocol per eligibility criteria of the master study and clinically appropriate to proceed with bevacizumab treatment at the discretion of the treating physician
- SUBSTUDY 1: Diagnosis of recurrent glioblastoma and intention to treat with bevacizumab
- NOTE: Any number of prior recurrences is permitted
- NOTE: Prior limited use of bevacizumab for radiation necrosis/treatment related edema is permitted. Prior use should not exceed four infusions with the last dose administered ≥ 4 weeks prior to enrollment in this substudy
- SUBSTUDY 1: Willing and able to adhere to the substudy for the duration of the substudy including undergoing treatment, and attending scheduled visits, and examinations
- SUBSTUDY 1: Negative pregnancy test ≤ 8 days prior to registration for persons of childbearing potential only
- SUBSTUDY 1: Provide written informed consent
- SUBSTUDY 1: Ability to complete assessments and questionnaires by themselves or with assistance
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Florida Coordinator of this site? Confirm its status | Jacksonville | United States | Recruiting |
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.